Status:
COMPLETED
Evaluation of the Effect of Different Doses Dexmedetomidine Infusion on Lung Mechanics and Oxygenation in Obese Patients
Lead Sponsor:
National Cancer Institute, Egypt
Conditions:
Obesity; Drug
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
Brief Summary
• The objective of this study is to evaluate the effect of different doses of dexmedetomidine infusion intraoperative on lung mechanics and oxygenation regarding PaO2/Fraction of inspired oxygen), Int...
Detailed Description
Dexmedetomidine is a selective agonist of α2receptorswhose tendency to α2 receptors is eight times more than that of clonidine. It also has powerful sedative, analgesic, anti-inflammatory, and organ pr...
Eligibility Criteria
Inclusion
- Age 18-60years
- Obese patients BMI\>25 Kg/meter square
- Patients undergoing laparoscopic cancer surgery.
Exclusion
- Heart failure
- Arrhythmias
- Severe liver or kidney impairment
- Patients with forced expiratory volume in 1 sec (FEV1)/FVC \< 70%
- Heart block
Key Trial Info
Start Date :
January 30 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 28 2022
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT04730375
Start Date
January 30 2021
End Date
February 28 2022
Last Update
May 5 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nataional Cancer Instituite
Cairo, Egypt